



JAZZ PHARMACEUTICALS LAUNCHES SLEEP MEDICINE FELLOWSHIP GRANT PROGRAM

March 26, 2007

Four \$50,000 One-Year Grants to Be Awarded for Original Research

Palo Alto, Calif., March 26, 2007 -- Jazz Pharmaceuticals, Inc. today announced the launch of the Jazz Pharmaceuticals Fellowship Training Grant in Sleep Medicine for physician and research Fellows conducting original peer-review research in sleep medicine. Four \$50,000 one-year grants will be awarded at the beginning of the 2008-2009 academic year to support promising research conducted by Fellows in accredited sleep training programs, or complementary programs focused in the field of sleep medicine.

The Jazz Pharmaceuticals Fellowship Training Grant in Sleep Medicine program was created to support the education of the next generation of sleep experts. The company has assembled a distinguished Fellowship Grant Committee comprised of ten clinicians and researchers, recognized for their work in the field of sleep, who will independently review applications and letters of intent from candidates in US training programs and select the winners. The grants will be awarded to the four Fellows' training institutions in support of research program costs.

According to the National Heart, Lung and Blood Institute of Health, an estimated 50 -70 million Americans suffer from debilitating sleep conditions which can significantly impede their ability to function in school, work and society. The majority of people currently suffering from sleep disorders are not diagnosed or appropriately treated. Through the Jazz Pharmaceuticals Fellowship Training Grant in Sleep Medicine, Jazz Pharmaceuticals aims to foster the advancement of sleep professionals in order to address this need.

Applying for a Jazz Pharmaceuticals Fellowship Training Grant in Sleep Medicine
Grant applicants must hold an M.D., D.O. or Ph.D. degree, and hold a full-time Fellow position in an accredited training program for the 2008-2009 academic year. The research project must be the primary work of the applicant, in collaboration with a qualified mentor. Equal consideration will be given to basic and clinical research projects. Initial applications, including a Letter of Intent and Curriculum Vitae, are to be submitted by applicants by July 31, 2007. Applicants will be notified of the committee's initial decision by August 15, 2007. If selected to proceed to the next step, applicants will be asked to submit a formal proposal by October 1, 2007. Grantees must devote a minimum of 50 percent of their training efforts to the project and must provide quarterly progress reports or summaries to Jazz Pharmaceuticals and to the Fellowship Grant Committee. For full application details, please visit: <http://www.jazzpharmaceuticals.com/grants.php>.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Based in Palo Alto, California, the company is committed to working closely with patients, patient advocacy groups and healthcare professionals. For further information, please visit www.JazzPharmaceuticals.com.

Contacts:

Jazz Pharmaceuticals, Inc.
BCC Partners
Karen L. Bergman, 650-575-1509
Michelle Corral, 415-794-8662

Jazz Pharmaceuticals, Inc.
Matthew Fust
Chief Financial Officer
650-496-3777
mediainfo@jazzpharma.com